Purpose: To determine the negative predictive value (NPV) of multiparametric magnetic resonance imaging (mp-MRI) for clinically significant cancer (CSC) based on the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 in very low-risk or low-risk prostate cancer patients.
INTRODUCTION
Active surveillance (AS) of low-risk prostate cancer patients is an established option for treatment planning. To select candidates for AS, clinicians have developed several methods that have been compared with regard to effectiveness.
1 Current inclusion criteria for AS of low-risk prostate cancer are typically based on prostate-specific antigen (PSA), Gleason score (GS), PSA density (PSAD), clinical staging, and number of positive biopsy cores. 2 ,3 However, we reported higher percentage rates of upgrading or upstaging in Korean patients based on 6 contemporary AS protocols. 4 Multiparametric magnetic resonance imaging (mp-MRI) of prostate has demonstrated great promise for detection of prostate cancer and clinically significant cancer (CSC). [5] [6] [7] [8] We previously demonstrated that tumor visibility on MRI using a Likert scale is helpful for detecting unfavorable disease. 9 The
Prostate Imaging and Report and Data System (PI-RADS) was developed by the European Society of Urogenital Radiology to standardize reporting of mp-MRI in 2012. 10, 11 The second version of PI-RADS was introduced to improve MRI interpretation in determining patients who have significant cancer. 12 Several studies showed that mp-MRI is a good modality for prostate cancer risk classification and that it predicts clinically significant cancer before radical prostatectomy (RP) and in AS of prostate cancer. 13, 14 However, the clinical utility of PI-RADS version 2 has not been fully validated.
Therefore, the purpose of this study was to analyze whether PI-RADS version 2 can predict CSC after RP in very low risk or low-risk prostate cancer patients.
MATERIALS AND METHODS

Data Collection
This retrospective study was approved by the Institutional patients with low-risk prostate cancer were retrospectively analyzed. Of the 380 patients, 142 patients were in the very low risk group (GS≤6, PSA＜10 ng/mL, positive cores ≤2, ≤50% of cancer in each core, PSAD＜0.15 ng/mL/g).
MRI Technique and Interpretation
All patients underwent mp-MRI with a 3.0T (Intera Achieva 
Outcomes and Statistical Analyses
In this study, CSC at RP was defined based on a recent study as any T3-4 or G3+4 with tumor volume ＞15% or G4+3 or higher in Korean patients. 16 In the very low risk group and low risk group, rate of CSC was analyzed according to each PI-RADS score using 2 groups (PI-RADS score of 4 or greater and PI-RADS score of less than 4). A p-value of ＜0.05 was considered statistically significant. All statistical analyses were performed using IBM SPSS Statistics ver. 23.0 (IBM Co., Armonk, NY, USA). Table 1 and 7%, respectively. The tumor volume in the low risk and very low risk groups are 3.49 mL and 2.80 mL, respectively.
RESULTS
In the low risk group, there were 20.8% (n=79) PI-RADS 20 reported that mp-MRI had a high NPV (89.7%) for detection of path-index lesions defined as cancer with a given prostate sextant on 2 separate biopsy sessions. In this study, the index lesion on MRI was defined as a single suspicious lesion ＞10 mm or ＞2 lesions in a given prostate sextant. Another study by Dianat et al. 21 showed that tumor invisibility on MRI was associated with a lower risk of adverse biopsy pathology. Among men with MRI-invisible tumors, 1 of 12 (8.5%) had pathologically adverse findings and 34 of 84 (40.5%) had adverse pathology in MRI visible tumors.
Previously, we also reported that visible tumor in mp-MRI using PI-RADS version 1 was associated with unfavorable disease after RP in candidates for AS. 9 Patients with MRI-visible cancer were more likely to have Gleason upgrading (49.8% vs.
14.3%, p＜0.001) and unfavorable disease (52.1% vs. 14.3%, p＜0.001) than patients with MRI-invisible tumor.
Recently, the second version of PI-RADS was designed for detection of clinically significant prostate cancer. Several studies have demonstrated the utility of PI-RADS version 2 in prostate cancer. Vargas et al. 22 reported that PI-RADS version 2 correctly identified 95% of prostate cancer foci ≥0.5 mL. Park et al. 7 demonstrated that PI-RADS score was only a significant factor for CSC. In this study, CSC was defined as follows: (1) surgical GS of 7 or greater, (2) 
CONCLUSIONS
In the very low risk group, the NPV of multiparametric prostate MRI (PI-RADS version 2) in clinically significant prostate cancer was high, but not in the low risk group. Therefore, tumors that were non-visible on multiparametric prostate MRI appear to be predictive of insignificant prostate cancer in the low risk group. With validation in further studies, multiparametric prostate MRI using PI-RADS version 2 will help to identify candidates for AS in the very low risk group.
